Canopy Growth Corporation — Form 10-Q Summary
Reporting period: Three months ended June 30, 2022, Canopy Growth’s first quarter of fiscal 2023 (not calendar-year Q1). The unaudited statements use U.S. GAAP and report amounts in Canadian dollars unless noted otherwise.
Business context and financial performance
Canopy produces and sells cannabis products in Canada and selected international markets, and consumer products including vaporizers, wellness and skincare items, and BioSteel sports nutrition products. Its reportable segments are global cannabis and other consumer products.
| Metric | Quarter ended June 30, 2022 | Prior-year quarter |
|---|---|---|
| Net revenue | $110.1 million | $136.2 million |
| Gross margin / margin rate | $(1.4) million / (1)% | $27.2 million / 20% |
| Operating loss | $(1,838.2) million | $(187.7) million |
| Net loss | $(2,087.6) million | Net income of $390.0 million |
| Adjusted EBITDA loss | $(74.8) million | $(63.6) million |
| Cash used in operating activities | $(140.5) million | $(165.8) million |
| Free cash flow | $(142.8) million | $(186.1) million |
Revenue declined 19% year over year. Global cannabis revenue fell 29% to $66.2 million; other consumer products revenue rose 1% to $43.9 million. Canadian recreational cannabis revenue dropped 35% to $39.0 million, while Canadian medical revenue was nearly unchanged at $13.4 million. BioSteel revenue grew 169% to $17.9 million, offset by declines at Storz & Bickel and This Works. The global cannabis segment posted a 23% gross margin loss rate; other consumer products maintained a 32% gross margin rate.
At June 30, cash and cash equivalents were $769.5 million and short-term investments were $447.6 million, together approximately $1.22 billion. Total debt carrying value was $1.46 billion, including $193.1 million classified as current; shareholders’ equity was $1.65 billion. Total assets fell to $3.52 billion from $5.62 billion, largely reflecting the goodwill write-down. Management said liquidity was adequate for operating needs, commitments and scheduled debt service for at least the next 12 months.
Material changes and unusual items
- Revenue fell $26.1 million year over year, mainly due to weaker Canadian recreational cannabis sales and the prior-year contribution from C3, divested in January 2022. Price compression, competition and lower sales of value-priced dried flower weighed on Canadian recreational results.
- Canopy recorded a $1.725 billion goodwill impairment, eliminating all goodwill assigned to its cannabis operations reporting unit. The assessment followed a decline in Canopy’s share price and relied significantly on share price and an estimated control premium. This noncash charge drove most of the reported net loss.
- Other expense, net was $245.6 million, versus other income of $580.7 million a year earlier. It included a $300.9 million loss from fair-value changes in other financial assets, partly offset by gains on the Acreage arrangement and CBI warrant liability. These investment and liability valuations are volatile and include significant estimates.
- Inventory write-downs were $12.2 million, versus $6.0 million a year earlier. Management cited lower production volumes, price compression, product mix, restructuring-related inventory costs and lower Canadian government payroll subsidies as factors behind the gross-margin deterioration.
- Operating cash outflow improved year over year, but remained substantial. Investing cash inflow of $121.4 million primarily reflected $154.0 million of net short-term investment redemptions; it should not be read as recurring operating cash generation.
Liquidity, debt, outlook and risks
The $750 million U.S.-dollar senior secured credit facility matures March 18, 2026, has no scheduled principal amortization and bears interest at LIBOR plus 8.50%, subject to a 1.00% floor. It is secured by substantially all assets of borrowers and guarantors and includes a minimum-liquidity covenant of US$200 million at each fiscal quarter-end. The agreement permits up to US$500 million of additional senior secured borrowing, subject to its terms.
In June and July 2022, Canopy exchanged and cancelled $262.6 million principal amount of its 4.25% notes due July 2023 for approximately $260.0 million of purchase price paid in shares, plus $5.4 million cash for accrued interest. The July 18 closing issued 62.7 million additional shares; including shares issued June 30, 76.8 million shares were issued in total. Note conversions following the indenture amendment must be settled in cash. The transaction reduced near-term note principal but materially diluted shareholders.
Canopy gave no specific revenue, earnings or margin guidance in the supplied filing text. Management stated it expects eventual business success and profitability, but cautioned that there is no assurance of adequate product acceptance or positive cash flow. It identified uncertainty around cannabis regulation, especially U.S. federal legalization and hemp/CBD rules; competition and price pressure; restructuring execution; consumer demand, inflation and supply-chain disruption; impairment risk; and the ability to fund operations, refinance debt and meet covenants. Potential acquisitions of Acreage and Wana depend on U.S. legal changes; Jetty rights are also tied to legal changes, with an earlier exercise option at Canopy’s discretion.
The company reported effective disclosure controls as of June 30, 2022, with no material change in internal control over financial reporting during the quarter. A securities class action settlement received final court approval on June 7, 2022; the company denied wrongdoing. The filing states there were no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether operating performance and gross margins improve after the steep decline in Canadian recreational sales and the negative global cannabis margin.
- Cash burn, investment redemptions and available liquidity relative to the US$200 million minimum-liquidity covenant and ongoing debt service.
- The remaining principal, cash-settlement exposure and maturity-related requirements for the 2023 notes after the exchange, and the dilution reflected in the post-quarter share count.
- Valuation assumptions behind the $1.725 billion goodwill impairment and Canopy’s fair-value-sensitive investments and contingent arrangements.
- Whether restructuring and cost-saving measures deliver sustainable benefits, and whether U.S. regulatory changes enable the contemplated acquisitions.